Chris Howerton
Stock Analyst at Jefferies
(2.55)
# 2,144
Out of 4,786 analysts
74
Total ratings
44.07%
Success rate
13.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $4.91 | +62.93% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $17.31 | +356.38% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $0.80 | +399.94% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $1 | $0.49 | +104.04% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $2.03 | +17,239.90% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $8.01 | +8,888.76% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.46 | -65.75% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $11.06 | -9.58% | 1 | Feb 8, 2023 | |
| MEIP MEI Pharma | Downgrades: Underperform | $8 → $2 | $2.19 | -8.68% | 3 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $7.83 | +40.49% | 3 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $70 → $40 | $21.87 | +82.90% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $33.19 | +83.79% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $116.63 | -22.83% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $4.59 | +161.44% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $126 | $1.15 | +10,856.52% | 1 | Dec 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.09 | +1,734.86% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $18.15 | +263.64% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.65 | +289.38% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.38 | +1,421.74% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $0.97 | +2,162.91% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.27 | +1,711.02% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $16.61 | +26.43% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $4 → $29 | $0.70 | +4,042.27% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $0.93 | +6,386.49% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $114.22 | -85.99% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $48.36 | -44.17% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.13 | +18,902.38% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $4.91
Upside: +62.93%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $17.31
Upside: +356.38%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $0.80
Upside: +399.94%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $1
Current: $0.49
Upside: +104.04%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $2.03
Upside: +17,239.90%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $8.01
Upside: +8,888.76%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.46
Upside: -65.75%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $11.06
Upside: -9.58%
MEI Pharma
Feb 8, 2023
Downgrades: Underperform
Price Target: $8 → $2
Current: $2.19
Upside: -8.68%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $7.83
Upside: +40.49%
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $21.87
Upside: +82.90%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $33.19
Upside: +83.79%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $116.63
Upside: -22.83%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $4.59
Upside: +161.44%
Dec 13, 2021
Maintains: Buy
Price Target: $101 → $126
Current: $1.15
Upside: +10,856.52%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $1.09
Upside: +1,734.86%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $18.15
Upside: +263.64%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $5.65
Upside: +289.38%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.38
Upside: +1,421.74%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $0.97
Upside: +2,162.91%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.27
Upside: +1,711.02%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $16.61
Upside: +26.43%
Aug 11, 2020
Upgrades: Buy
Price Target: $4 → $29
Current: $0.70
Upside: +4,042.27%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $0.93
Upside: +6,386.49%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $114.22
Upside: -85.99%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $48.36
Upside: -44.17%
May 26, 2020
Initiates: Buy
Price Target: $24
Current: $0.13
Upside: +18,902.38%